Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Runcaciguat (BAY1101042) in Healthy Males
NCT03252002Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of runcaciguat in chronic kidney disease (CKD) and diabetic retinopathy (DR) (6 arms), sponsored by Bayer. Primary endpoint: Number of treatment emergent adverse events at 19 days. Started Aug 2017; status: completed.
02
Drugs
runcaciguat
03
Conditions
chronic kidney disease (CKD)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03252002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252002.